Ertapenem is an antibiotic that falls into the carbapenem class. Its synthesis patent application in the United States is a key aspect of its market exclusivity and the potential for generic competition.
When does the ertapenem patent expire?
The primary patents protecting ertapenem have expired, opening the door for generic versions. For instance, U.S. Patent No. 5,731,301, which covers ertapenem and its salts, expired in November 2017. Other related patents may have had different expiry dates. Information on specific patent expiry dates for pharmaceuticals can be tracked through resources like DrugPatentWatch.com [1].
What is ertapenem and how is it made?
Ertapenem is a carbapenem antibiotic used to treat serious bacterial infections. It works by inhibiting bacterial cell wall synthesis. The synthesis of ertapenem involves complex organic chemistry, typically starting from precursors like derivatives of penicillin or cephalosporin. The process involves several chemical steps to build the core carbapenem structure and introduce the specific side chains that define ertapenem's activity.
Who makes ertapenem and its generics?
The original manufacturer of ertapenem was Merck & Co., which marketed it under the brand name Invanz. Following patent expiries, several companies have developed and are marketing generic versions of ertapenem.
Can generic ertapenem be sold before patent expiry?
Generally, generic versions of a drug cannot be legally marketed in the United States before the relevant patents and market exclusivities expire. The Hatch-Waxman Act established an abbreviated new drug application (ANDA) process for generic drugs, which allows for approval once these protections lapse. However, there can be legal challenges and patent litigation that affect the exact timing of generic market entry.
What are the legal challenges to ertapenem patents?
Pharmaceutical patents are frequently subject to legal challenges from generic manufacturers seeking to bring their products to market earlier. These challenges can involve claims of patent invalidity or non-infringement. The specific litigation history for ertapenem patents would detail any such disputes and their outcomes, influencing the timeline for generic availability.
How do ertapenem patents affect drug pricing?
The existence of patents grants market exclusivity to the innovator company, allowing them to set prices without direct competition. Once patents expire and generic versions become available, competition typically leads to significant price reductions.
What are the risks associated with ertapenem?
Like all medications, ertapenem carries potential risks and side effects. Common side effects can include diarrhea, nausea, headache, and injection site reactions. More serious risks, though less common, may include allergic reactions and the development of Clostridium difficile-associated diarrhea. Patients should discuss these risks with their healthcare providers.
What are alternative treatments for infections treated by ertapenem?
Depending on the specific bacterial infection and its susceptibility, alternative treatments to ertapenem may include other carbapenems, beta-lactam/beta-lactamase inhibitor combinations, or other classes of antibiotics. The choice of treatment is guided by factors such as the type of infection, local resistance patterns, patient allergies, and severity of illness.
Sources
1. https://drugpatentwatch.com/